Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering DrugsHye Won Lee, John Wilding, Kamlesh Khunti et al.|Journal of the American College of Cardiology|2018Cited by 465
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort studyShun Kohsaka, Dianna J. Magliano, Matthias Saathoff et al.|The Lancet Diabetes & Endocrinology|2020Cited by 93
The Relationship between COVID-19 and Hypothalamic–Pituitary–Adrenal Axis: A Large Spectrum from Glucocorticoid Insufficiency to Excess—The CAPISCO International Expert PanelMojca Jensterle, Manfredi Rizzo, Rok Herman et al.|International Journal of Molecular Sciences|2022Cited by 69
Post-COVID syndrome, inflammation, and diabetesAli A. Rizvi, Manfredi Rizzo, Amita Kathuria et al.|Journal of Diabetes and its Complications|2022Cited by 69
Promoting a Syndemic Approach for Cardiometabolic Disease Management During COVID-19: The CAPISCO International Expert PanelWael Al Mahmeed, Khalid Al‐Rasadi, Yajnavalka Banerjee et al.|Frontiers in Cardiovascular Medicine|2021Cited by 48